SESSION TITLE: Procedures 1 - EMN/BT/Rigid/Cryo
SESSION TYPE: Original Investigation Poster
PRESENTED ON: Wednesday, October 26, 2016 at 01:30 PM - 02:30 PM
PURPOSE: Bronchial Thermoplasty (BT) is a one-time treatment recommended as a GINA Step 5 add-on treatment for severe uncontrolled asthma. Omalizumab (OM) is similarly recommended as a GINA Step 5 add-on treatment for uncontrolled asthma and these two treatments may be evaluated by clinicians as alternatives to one another. In the midst of discussions within the US regarding high drug costs for monoclonal antibody therapies, clinicians may consider the acute costs of a procedural treatment a reasonable alternative. However, no clinical trials have directly compared BT and OM to afford clinicians the ability to compare relative clinical efficacy as well as costs. Thus, an indirect treatment comparison (ITC) is presented using optimized asthma therapy (OAT) as a common control. ITCs are often utilised in health technology assessment to establish comparative effectiveness in the absence of direct trial evidence. We extend these results with a three year simulation of costs of care delivered and differences in asthma-related healthcare utilization.